John W. Bristol & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$85.8M Sell
561,837
-7,881
-1% -$1.21M 1.41% 34
2025
Q4
$78.5M Sell
569,718
-12,005
-2% -$1.57M 1.21% 38
2025
Q3
$74.6M Sell
581,723
-10,558
-2% -$1.29M 1.18% 39
2025
Q2
$71.7M Sell
592,281
-1,445
-0.2% -$163K 1.16% 41
2025
Q1
$66.2M Sell
593,726
-15,956
-3% -$1.7M 1.13% 42
2024
Q4
$59.3M Sell
609,682
-14,027
-2% -$1.5M 0.97% 40
2024
Q3
$71.7M Sell
623,709
-1,214
-0.2% -$138K 1.15% 40
2024
Q2
$66.5M Sell
624,923
-13,635
-2% -$1.37M 1.08% 41
2024
Q1
$61.8M Sell
638,558
-4,197
-0.7% -$430K 1.05% 42
2023
Q4
$64.9M Sell
642,755
-32,654
-5% -$3.15M 1.19% 43
2023
Q3
$68.8M Sell
675,409
-7,121
-1% -$723K 1.36% 39
2023
Q2
$68.9M Sell
682,530
-4,491
-0.7% -$449K 1.3% 41
2023
Q1
$63.2M Buy
687,021
+3,818
+0.6% +$333K 1.3% 38
2022
Q4
$62M Buy
683,203
+3,537
+0.5% +$298K 1.47% 37
2022
Q3
$51.7M Sell
679,666
-10,228
-1% -$848K 1.29% 40
2022
Q2
$58.3M Sell
689,894
-18,724
-3% -$1.64M 1.43% 35
2022
Q1
$62.2M Sell
708,618
-16,862
-2% -$1.46M 1.23% 41
2021
Q4
$63.5M Sell
725,480
-8,764
-1% -$728K 1.1% 44
2021
Q3
$60M Sell
734,244
-11,024
-1% -$992K 1.12% 44
2021
Q2
$68M Sell
745,268
-5,776
-0.8% -$514K 1.25% 40
2021
Q1
$64.2M Sell
751,044
-3,681
-0.5% -$330K 1.31% 41
2020
Q4
$71.3M Sell
754,725
-1,097
-0.1% -$95.9K 1.47% 35
2020
Q3
$65.7M Buy
755,822
+4,239
+0.6% +$367K 1.49% 32
2020
Q2
$65.6M Sell
751,583
-16,598
-2% -$1.43M 1.63% 31
2020
Q1
$63.3M Sell
768,181
-9,903
-1% -$884K 1.97% 27
2019
Q4
$73.7M Sell
778,084
-2,380
-0.3% -$214K 1.78% 28
2019
Q3
$67.8M Sell
780,464
-4,529
-0.6% -$407K 1.76% 29
2019
Q2
$71.7M Sell
784,993
-100,379
-11% -$8.5M 1.85% 28
2019
Q1
$76.3M Sell
885,372
-4,120
-0.5% -$331K 2.05% 25
2018
Q4
$68.4M Sell
889,492
-52,838
-6% -$4.11M 2.15% 23
2018
Q3
$72.8M Sell
942,330
-10,360
-1% -$766K 1.92% 27
2018
Q2
$64.5M Buy
952,690
+2,525
+0.3% +$174K 1.83% 32
2018
Q1
$68.8M Sell
950,165
-14,614
-2% -$1.11M 1.95% 28
2017
Q4
$72.6M Sell
964,779
-45,855
-5% -$3.46M 2.06% 25
2017
Q3
$77.7M Sell
1,010,634
-41,263
-4% -$3.12M 2.25% 13
2017
Q2
$78.7M Sell
1,051,897
-130,747
-11% -$9.27M 2.31% 10
2017
Q1
$78.7M Buy
1,182,644
+246,915
+26% +$16.5M 2.17% 17
2016
Q4
$61.1M Sell
935,729
-33,269
-3% -$2.16M 1.72% 33
2016
Q3
$68.6M Buy
968,998
+91,210
+10% +$6.65M 1.88% 24
2016
Q2
$64.9M Sell
877,788
-50,181
-5% -$3.47M 1.83% 27
2016
Q1
$60.2M Sell
927,969
-32,588
-3% -$2.22M 1.63% 36
2015
Q4
$74.1M Sell
960,557
-26,230
-3% -$2.08M 1.95% 22
2015
Q3
$81.3M Sell
986,787
-165,376
-14% -$14.7M 2.17% 16
2015
Q2
$102M Sell
1,152,163
-91,169
-7% -$8.36M 2.17% 14
2015
Q1
$110M Sell
1,243,332
-133,407
-10% -$11.8M 2.2% 15
2014
Q4
$114M Sell
1,376,739
-36,723
-3% -$3.04M 2.08% 24
2014
Q3
$119M Sell
1,413,462
-55,595
-4% -$4.5M 2.14% 20
2014
Q2
$119M Sell
1,469,057
-33,249
-2% -$2.62M 2.02% 22
2014
Q1
$114M Sell
1,502,306
-18,048
-1% -$1.32M 2% 22
2013
Q4
$110M Sell
1,520,354
-57,908
-4% -$4.03M 1.94% 27
2013
Q3
$108M Sell
1,578,262
-120,573
-7% -$7.98M 2.03% 22
2013
Q2
$108M Buy
+1,698,835
New +$111M 1.97% 24

Other funds holding NVS

John W. Bristol & Co's NVS Position: Q1 2026 in Review

John W. Bristol & Co reduced its Novartis (NVS) stake by 1.4% in Q1 2026, selling an estimated $1.21M and leaving 561,837 shares worth $85.8M. The position accounts for 1.41% of the portfolio, ranked #34.

John W. Bristol & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $119M in Q3 2014. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • John W. Bristol & Co held 561,837 shares of Novartis worth $85.8M as of Q1 2026.
  • John W. Bristol & Co sold 7,881 Novartis shares in Q1 2026, an estimated $1.21M.
  • Novartis made up 1.41% of John W. Bristol & Co's portfolio in Q1 2026, its #34 holding.
  • John W. Bristol & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • John W. Bristol & Co's Novartis position peaked at $119M in Q3 2014.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on John W. Bristol & Co's 13F filing for Q1 2026, filed 14 May 2026.